Beyfortus (nirsevimab) RSV immunoglobulin 

RSV shots are available to newborns in their first winter (and second winter for certain high risk diagnoses) between October to March.

​East Bay Pediatrics is proud to offer the respiratory syncytial virus (RSV) monoclonal antibody injection Beyfortus (nirsevimab) in our office. This injection provides antibody protection against RSV to babies under 8 months old and to high risk infants in their first and second winter seasons. The goal is to decrease infant hospitalization and death from this annual winter virus. The injection has been shown to be safe in clinical trials, with few side effects. Infants who receive it will need to be observed in the office for 15 minutes after the injection. 

https://www.beyfortus.com/#important-safety-information

High risk infants (significantly premature, congenital heart disease, chronic lung disease) still qualify for Synagis which is a monthly vaccine against RSV. This vaccine requires prior authorization. 

In 2023, an RSV vaccine designed for pregnant women was developed. We encourage pregnant mothers to ask their OB about getting Abrysvo between weeks 32 to 36 of pregnancy to protect the baby from this respiratory virus. Infants of mothers who receive the RSV vaccine for pregnant women do not need to take the RSV injection for newborns.
NOTE: do not confuse this maternal vaccine with Arexvy which is the RSV vaccine for those over 60 years old. Baby's grandparents can get Arexvy but this does not give babies direct protection.

As you know East Bay Pediatrics strongly supports vaccination of all children. We are very excited that infants may be afforded better protection against RSV.